Geron (NASDAQ: [[ticker:GERN]]) said today that CEO Thomas Okarma has left the company as president, CEO, and as a member of the board of directors. The Menlo Park, CA-based developer of stem cell therapies said David Greenwood, the company’s chief financial officer, will step up as president and interim CEO, and will take a board seat. Hoyoung Huh, a member of the board, is taking on a new role as executive chairman.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
